MGNX - Bathi operasional EBITDA MacroGenics

MacroGenics, Inc. (MGNX) is fighting for leadership in oncology, competing with global tech giants in the precision of clinical data. The growth of the company's operating result before depreciation and amortization confirms the effectiveness of the DART platform, which targets and destroys tumors with precision. Strategic alliances and licensing deals are strengthening the financial foundation. The value of 0.00 expresses the latest metric level, capturing the current amplitude of cash flows from operating activities.

MacroGenics, Inc. (MGNX) - Bathi operasional EBITDA saka 23.11.2025 nganti 10.11.2026

Ringkesan rincian data analitis MacroGenics (MGNX)

- kuotasi saiki lan rata-rata prakiraan nilai:

Kutipan saham MacroGenics Inc.|MGNX - Prakiraan konsensus analis

- statistik kapitalisasi pasar:

Kapitalisasi pasar MacroGenics|MGNX - Nilai Total Perusahaan

- indikator nilai buku ekuitas:

Ekuitas saben Saham MacroGenics|MGNX - Kapitalisasi Buku|Rasio Kapitalisasi marang Aset Bersih macrogenics.com|MGNX - Total Aset Perusahaan

- data tingkat utang lan likuiditas finansial:

- indikator bathi lan kelipatan valuasi:

MGNX - Bathi resik perusahaan|Penghasilan resik sing dikarepake MacroGenics, Inc.|MGNX - Rasio rega marang bathi|Rasio prakiraan rega marang bathi macrogenics.com|MGNX - Pangali PEG|Pangali nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan MacroGenics|MGNX - Bathi operasional EBITDA|Bathi resik saben siji saham sajrone rolas wulan pungkasan MacroGenics|MGNX - Bathi saben saham sajrone rolas wulan pungkasan|Wutah bathi saben saham taun-ka-taun sajrone 12 wulan pungkasan macrogenics.com|MGNX - Wutah bathi ing taun lumaku|Prakiraan konsensus wutah bathi saben saham kanggo taun ngarep MacroGenics, Inc.

Analisis kabeh metrik perusahaan:MGNX - MacroGenics Inc.

This indicator captures the cash volume of the operating result, demonstrating the core business's ability to generate profit before depreciation and taxes. Analyzing absolute operating profit allows for an assessment of MacroGenics, Inc. (MGNX) resilience to market shocks, which is critical when scaling therapeutic regimens and expanding the network of medical centers through partnerships with global pharmaceutical behemoths.

Karo sapa MacroGenics, Inc. saingan

OLMA - Bathi operasional sadurunge ngurangi amortisasi|Puma Biotechnology Inc - Bathi operasional EBITDA|GLSI - Bathi operasional EBITDA|Zentalis (ZNTL) - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi operasional sadurunge amortisasi PSTV|PCSA (Processa Pharmaceuticals Inc.) - Bathi operasional EBITDA|Bathi operasional sadurunge ngurangi amortisasi Eagle Pharma (EGRX)